



# Corrigendum: Associations of Serum S100A12 With Severity and Prognosis in Patients With Community-Acquired Pneumonia: A Prospective Cohort Study

Xiao Jiang<sup>1†</sup>, Chun-Mei Huang<sup>2†</sup>, Chun-Mei Feng<sup>3</sup>, Zheng Xu<sup>3</sup>, Lin Fu<sup>3,4\*</sup> and Xin-Ming Wang<sup>5,6\*</sup>

## OPEN ACCESS

### Approved by:

Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

### \*Correspondence:

Xin-Ming Wang  
wangxim@ahmu.edu.cn  
Lin Fu  
fulin@ahmu.edu.cn

<sup>†</sup>These authors have contributed  
equally to this work

### Specialty section:

This article was submitted to  
Inflammation,  
a section of the journal  
*Frontiers in Immunology*

Received: 16 November 2021

Accepted: 17 November 2021

Published: 10 February 2022

### Citation:

Jiang X, Huang C-M, Feng C-M, Xu Z, Fu L and Wang X-M (2022)  
Corrigendum: Associations of Serum S100A12 With Severity and Prognosis in Patients With Community-Acquired Pneumonia: A Prospective Cohort Study.  
*Front. Immunol.* 12:815903.  
doi: 10.3389/fimmu.2021.815903

<sup>1</sup> Department of Nephrology, First Affiliated Hospital of Anhui Medical University, Hefei, China, <sup>2</sup> Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China, <sup>3</sup> Respiratory and Critical Care Medicine, Second Affiliated Hospital of Anhui Medical University, Hefei, China, <sup>4</sup> Department of Toxicology, Anhui Medical University, Hefei, China, <sup>5</sup> Department of Pharmacy, First Affiliated Hospital of Anhui Medical University, Hefei, China, <sup>6</sup> Third-Grade Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, China

**Keywords:** S100A12, community-acquired pneumonia, CAP severity score, prognosis, biomarker

### A Corrigendum on:

#### Associations of Serum S100A12 With Severity and Prognosis in Patients With Community-Acquired Pneumonia: A Prospective Cohort Study

By Jiang X, Huang C-M, Feng C-M, Xu Z, Fu L and Wang X-M (2021). *Front. Immunol.* 12:714026.  
doi: 10.3389/fimmu.2021.714026

There is an error in the ethics name and number in the section of **Study Design and Subjects**. The correct ethics name and number is “Ethics Committee of Second Affiliated Hospital of Anhui Medical University (YX2021-085)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Jiang, Huang, Feng, Xu, Fu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.